Summary
The pharmacokinetics of pyridostigmine was evaluated after intravenous injection in two healthy male volunteers and after oral administration to five subjects. Plasma concentrations of pyridostigmine were determined after ion pair extraction from plasma and analysis by gas chromatography — mass spectrometry with chemical ionization, using d6-pyridostigmine as internal standard. Degradation of pyridostigmine in vitro was compensated for by use of the deuterated internal standard and by rapid cooling and separation of plasma after blood sampling. After intravenous administration of pyridostigmine 2.5 mg the plasma elimination half-life was 1.52 h, the volume of distribution was 1.43 l/kg and the plasma clearance 0.65 l/kg × h. The pharmacokinetic constants were very similar after oral administration of pyridostigmine 120 mg; the elimination half-life was 1.78±0.24 h, the volume of distribution 1.64±0.29 l/kg and the plasma clearance was 0.66±0.22 l/kg × h. The bioavailability was calculated to be 7.6±2.4%. When pyridostigmine was taken together with food, the time to reach the peak plasma concentration was prolonged from 1.7 to 3.2 h. Bioavailability, however, was not influenced by concomitant food intake. “Steady-state” plasma concentrations of pyridostigmine were measured in myasthenic patients on their ordinary dose schedule of cholinesterase inhibitor drugs. More than a seven-fold difference in steady-state plasma concentration was found between patients taking approximately the same daily dose of pyridostigmine.
Similar content being viewed by others
References
Aquilonius SM, Eckernäs SÅ, Hartvig P, Hultman J, Lindström B, Osterman PO (1979) A pharmacokinetic study of neostigmine in man using gas chromatography mass spectrometry. Eur J Clin Pharmacol 15: 367–371
Beermann B, Hellström K, Rosén A (1972) Gastrointestinal absorption of certain anticholinergic drugs. Eur J Clin Pharmacol 5: 83–92
Calvey TN, Chan K (1977) Plasma pyridostigmine levels in patients with myasthenia gravis. Clin Pharmacol Ther 21: 187–193
Chan K, Williams NE, Baty JD, Calvey TN (1976) A quantitative gas liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma. J Chromatogr 120: 349–358
Chan K, Calvey TN (1977) Renal clearance of pyridostigmine in patients with myasthenia gravis. Eur Neurol 10: 69–72
Chan K, Calvey TN (1978) Plasma concentration and effect in myasthenia gravis. Clin Pharmacol Ther 22: 596–601
Cohan SL, Pohlmann LW, Mikswewski J, O'Doherty DS (1976) The pharmacokinetics of pyridostigmine. Neurology 26: 536–539
Cohan SL, Dretchen KL, Neal A (1977) Malabsorption of pyridostigmine in patients with myasthenia gravis. Neurology 27: 299–301
Kornfeld P, Samuels AJ, Wolf RL, Osserman KE (1970) Metabolism of14C-labelled pyridostigmine in myasthenia gravis. Neurology 20: 634–641
Kornfeld P, Wolf RL, Samuels AJ, Osserman KE (1971) The effect of chronic pyridostigmine administration on14C-pyridostigmine metabolism in myasthenia gravis. Neurology 21: 550–552
Melander A (1978) Influence of food on the bioavailability of drug. Clin Pharmacokinet 3: 337–351
Sundwall A, Vessman J, Strindberg B (1973) Fate of emepronium in man in relation to its pharmacological effects. Eur J Clin Pharmacol 6: 191–195
Urban R (1951) US Patent 2 572 579
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Aquilonius, S.M., Eckernäs, S.Å., Hartvig, P. et al. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur J Clin Pharmacol 18, 423–428 (1980). https://doi.org/10.1007/BF00636797
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00636797